LeMaitre Vascular (NASDAQ:LMAT) Releases FY 2026 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 2.930-3.080 for the period, compared to the consensus estimate of 2.900. The company issued revenue guidance of $277.0 million-$283.0 million, compared to the consensus revenue estimate of $279.5 million. LeMaitre Vascular also updated its Q2 2026 guidance to 0.790-0.840 EPS.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on LMAT shares. Roth Mkm reaffirmed a “buy” rating and set a $117.00 target price (up from $108.00) on shares of LeMaitre Vascular in a research report on Thursday, February 26th. Zacks Research raised LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research note on Monday, April 13th. Barrington Research raised their price objective on LeMaitre Vascular from $95.00 to $105.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Citizens Jmp lifted their price objective on LeMaitre Vascular from $113.00 to $118.00 and gave the stock a “market outperform” rating in a research note on Thursday, February 26th. Finally, Wells Fargo & Company upped their target price on LeMaitre Vascular from $87.00 to $94.00 and gave the company an “equal weight” rating in a report on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $105.80.

LeMaitre Vascular Trading Up 0.7%

LMAT traded up $0.79 during trading on Tuesday, reaching $112.32. 225,458 shares of the stock traded hands, compared to its average volume of 204,146. The company has a quick ratio of 10.95, a current ratio of 12.89 and a debt-to-equity ratio of 0.43. The stock’s 50-day moving average is $108.90 and its 200 day moving average is $93.99. LeMaitre Vascular has a 12 month low of $78.35 and a 12 month high of $118.01. The stock has a market capitalization of $2.57 billion, a PE ratio of 44.75, a P/E/G ratio of 3.23 and a beta of 0.60.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.02. The firm had revenue of $66.55 million during the quarter, compared to analyst estimates of $66.67 million. LeMaitre Vascular had a return on equity of 14.72% and a net margin of 23.13%.LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. Equities analysts anticipate that LeMaitre Vascular will post 2.89 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 26th. Shareholders of record on Thursday, March 12th were issued a $0.25 dividend. The ex-dividend date was Thursday, March 12th. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.20. This represents a $1.00 dividend on an annualized basis and a yield of 0.9%. LeMaitre Vascular’s dividend payout ratio is presently 39.84%.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 150,000 shares of the stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $106.76, for a total transaction of $16,014,000.00. Following the transaction, the chief executive officer directly owned 1,532,304 shares in the company, valued at approximately $163,588,775.04. This represents a 8.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director David B. Roberts sold 8,464 shares of the firm’s stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $106.80, for a total transaction of $903,955.20. Following the sale, the director directly owned 17,979 shares of the company’s stock, valued at approximately $1,920,157.20. This trade represents a 32.01% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 215,438 shares of company stock valued at $23,062,911. 7.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On LeMaitre Vascular

Several institutional investors have recently made changes to their positions in LMAT. Mercer Global Advisors Inc. ADV boosted its position in shares of LeMaitre Vascular by 11.5% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 3,606 shares of the medical instruments supplier’s stock worth $292,000 after purchasing an additional 371 shares in the last quarter. NewEdge Advisors LLC increased its position in LeMaitre Vascular by 4.6% in the 4th quarter. NewEdge Advisors LLC now owns 3,158 shares of the medical instruments supplier’s stock valued at $256,000 after buying an additional 139 shares in the last quarter. Empowered Funds LLC bought a new stake in LeMaitre Vascular in the 4th quarter valued at about $289,000. nVerses Capital LLC bought a new stake in LeMaitre Vascular in the 4th quarter valued at about $234,000. Finally, Voloridge Investment Management LLC raised its stake in LeMaitre Vascular by 70.0% during the 4th quarter. Voloridge Investment Management LLC now owns 62,909 shares of the medical instruments supplier’s stock worth $5,102,000 after buying an additional 25,901 shares during the period. Institutional investors and hedge funds own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.